Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 52.51

+2.7%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (9156)	9/18/2003 10:40:29 AM
From: Biomaven	Read Replies (2) of 52153

Travel distance survival bias. I've had a chance to read the paper itself now, and here are a few comments: 1. It's based on just 110 people 2. They compared outcomes within each cancer center, so my first thought, which was that people travel further to the better centers, was wrong. 3. There is considerable interaction between race and travel distance and survival. African Americans actually did more than three times better than whites (hazard ratio for survival of .3), but the people who travelled more than 15 miles were predominantly white (91% white vs only 23% white for the closer patients). 4. Thus I'm left wondering if the multivariable Cox regression model they used (which adjusted for status like race) might not be the real driver behind their results. I just don't know enough statistics to really understand if this might be the case or not. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next